stockportfolio.pro
Septerna, Inc. (SEPN)
Healthcare · Biotechnology · NasdaqGM
Septerna, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $151,000 | $1.07M | $45.95M |
| Gross profit | — | — | — | — |
| Net income | $-27.68M | $4.18M | $-71.80M | $-48.88M |
| Net margin | — | 2768.2% | -6678.9% | -106.4% |
Source: Septerna, Inc. SEC filings (10-K).
What growth is priced into SEPN stock?
At today's market cap of $1.48B, Septerna, Inc. is priced for free-cash-flow growth of about 2.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $109.67M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Septerna, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SEPN in your portfolio →
Septerna, Inc. financial history by metric
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Septerna, Inc. — frequently asked questions
What is Septerna, Inc.'s revenue?
Septerna, Inc. (SEPN) reported revenue of $45.95M for fiscal year 2025, up 4174.5% from the prior year, according to its SEC filings.
Is Septerna, Inc. profitable?
No — SEPN reported a net loss of $-48.88M in fiscal 2025.
What is SEPN's P/E ratio?
Septerna, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Septerna, Inc. have?
As of fiscal year 2025, SEPN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Septerna, Inc.'s market cap?
Septerna, Inc. (SEPN) has a market capitalization of about $1.48B, based on the latest data in our nightly-refreshed cache.
When does Septerna, Inc.'s fiscal year end?
SEPN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SEPN stock?
At today's market cap of $1.48B, Septerna, Inc. is priced for free-cash-flow growth of about 2.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $109.67M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Septerna, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.